University of Manitoba, Department of Immunology, Room 417 Apotex Center, 750 McDermot Avenue, Winnipeg, Manitoba, R3E 0T5, Canada.
Immunotherapy. 2010 Sep;2(5):685-95. doi: 10.2217/imt.10.44.
Dendritic cells are professional antigen-presenting cells that initiate, regulate and shape the induction of specific immune responses. The ability to use dendritic cells in the induction of antigen-specific tolerance, antigen-specific immunity or specific differentiation of T-helper subsets holds great promise in dendritic cell-based immunotherapy of various diseases such as cancer, viral infections, allergy, as well as autoimmunity. Replication-incompetent HIV-1-based lentiviral vector is now emerging as a promising delivery system to genetically modify dendritic cells through antigen recognition, costimulatory molecules and/or polarization signals for the manipulation of antigen-specific immunity in vivo. This article discusses some of the recent advances in the uses of lentiviral vectors in dendritic cell-based immunotherapy.
树突状细胞是专业的抗原呈递细胞,能够启动、调节和塑造特定免疫反应的诱导。利用树突状细胞诱导抗原特异性耐受、抗原特异性免疫或 T 辅助细胞亚群的特异性分化,在基于树突状细胞的各种疾病的免疫治疗中具有巨大的应用前景,如癌症、病毒感染、过敏以及自身免疫性疾病等。目前,基于复制缺陷型 HIV-1 的慢病毒载体作为一种有前途的递呈系统,正在通过抗原识别、共刺激分子和/或极化信号来对树突状细胞进行基因修饰,从而在体内对抗原特异性免疫进行操控。本文讨论了慢病毒载体在基于树突状细胞的免疫治疗中的一些最新进展。